High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma

[1]  B. Seliger,et al.  Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. , 2008, Tissue antigens.

[2]  S. Ferrone,et al.  Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. , 2003, Tissue antigens.

[3]  N. Cascinelli,et al.  Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. , 2003, Cancer research.

[4]  P. Coulie,et al.  T-cell responses of vaccinated cancer patients. , 2003, Current opinion in immunology.

[5]  Nitin J. Karandikar,et al.  Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. , 2003, Blood.

[6]  A. Mackensen,et al.  Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients 1 , 2003, The Journal of Immunology.

[7]  T. Whiteside,et al.  Effector CD8+CD45RO−CD27−T cells have signalling defects in patients with squamous cell carcinoma of the head and neck , 2003, British Journal of Cancer.

[8]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Mark J. Smyth,et al.  Functional significance of the perforin/granzyme cell death pathway , 2002, Nature Reviews Immunology.

[10]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[11]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[12]  M. Takiguchi,et al.  Differentiation of Human CD8+ T Cells from a Memory to Memory/Effector Phenotype1 , 2002, The Journal of Immunology.

[13]  D. Jäger,et al.  Clinical cancer vaccine trials. , 2002, Current opinion in immunology.

[14]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[15]  Danila Valmori,et al.  Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans , 2002, The Journal of experimental medicine.

[16]  Y. Tokura,et al.  Interleukin‐10 expressed at early tumour sites induces subsequent generation of CD4+ T‐regulatory cells and systemic collapse of antitumour immunity , 2001, Immunology.

[17]  Frank O. Nestle,et al.  Dendritic cells: On the move from bench to bedside , 2001, Nature Medicine.

[18]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[19]  A. Mackensen,et al.  Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells. , 1999, European cytokine network.

[20]  V. Cerundolo,et al.  An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions , 1999, The Journal of experimental medicine.

[21]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[22]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[23]  P. Kloetzel,et al.  The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.

[24]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[25]  M. Rep,et al.  Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells , 1997, The Journal of experimental medicine.

[26]  P. Bruggen,et al.  T cell defined tumor antigens , 1997 .

[27]  T. Wobbes,et al.  Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. , 1997, Cancer research.

[28]  P. Coulie,et al.  Tumor antigens recognized by T cells. , 1997, Immunology today.

[29]  Halpern Ac,et al.  Prognostic models in melanoma. , 1997 .

[30]  Theresa,et al.  Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[32]  Marcus Groettrup,et al.  Incorporation of major histocompatibility complex – encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon‐γ , 1995, European journal of immunology.

[33]  P. Kourilsky,et al.  T-cell repertoire diversity and clonal expansions in normal and clinical samples. , 1995, Immunology today.

[34]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[35]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[36]  G. Carcelain,et al.  Direct evidence to support the immunosurveillance concept in a human regressive melanoma. , 1994, The Journal of clinical investigation.

[37]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[38]  M. Matsuda,et al.  Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. , 1993, Cancer research.

[39]  E. Podack,et al.  Perforin mRNA in primary peritoneal exudate cytotoxic T lymphocytes. , 1989, Journal of immunology.

[40]  D. Ahmann,et al.  Phase II study of recombinant leukocyte a interferon (rIFN‐αA) in disseminated malignant melanoma , 1984, Cancer.

[41]  P. Cresswell,et al.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids , 2004, Immunogenetics.

[42]  R. Tampé,et al.  Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. , 2001, Tissue antigens.

[43]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.